Novartis

4Q Revenues: $12.4 billion (+8%)

4Q Earnings: $1.1 billion (-5%)

FY Revenues: $47.4 billion (+6%)  

FY Earnings: $11.7 billion (-7%)

Comments: Pharmaceuticals sales grew 12% to $6.2 billion in the quarter, driven by continued momentum of Entresto with sales of $518 million, up 63%, and Cosentyx with $965 million in sales, up 20%, and the launch uptake of Zolgensma with $186 million in sales. Oncology sales grew 7% driven by continued momentum on Kisqali with $155 million in sales, up 158%, and Kymriah with $96 million in sales, and the launch uptake of Piqray with $67 million in sales. Generic competition had a negative impact of 2 percentage points. Gilenya sales were $803 million, down 4%. Zolgensma sales were $186 million, continued a strong launch performance. Xolair sales were $303 million, up 13% in the quarter. Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew to $425 million, up 9%, driven by growth in Europe from Hyrimoz, Rixathon and Erelzi, partly offset by one-time sales reversals in biopharmaceutical contract manufacturing.